Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Trehalose sparked curiosity as far back as the 19th century when scientists noticed it in mushrooms and insects. Back then, no one pictured this sugar emerging in drug manufacturing or vaccine stabilization. Decades rolled on before Japanese researchers in the 1990s cracked the scalable enzymatic production process, unlocking its use in food, cosmetics, and pharmaceuticals. Pharmaceutical trehalose only really got industry attention in the early 2000s, once drug companies realized it could stabilize proteins and address some of the toughest formulation headaches. Now, pharmaceutical-grade trehalose—often referred to by designations like BP, EP, and USP—lines the shelves of companies building next-generation therapies and vaccines.
Trehalose dihydrate in the pharma world means high standards: low microbial counts, precise moisture, and batch consistency that can withstand scrutiny. Companies produce it as a crystalline white powder made to dissolve rapidly and without fuss, supporting applications in lyophilized drugs, protein formulation, or injectable solutions. Unlike table sugar or sucrose, trehalose holds a unique structure and impresses with a lack of color formation during high-heat processes. It doesn’t just sweeten or bulk up formulas—it preserves active pharmaceutical ingredients (APIs) and helps reduce protein aggregation. Pharmaceutical trehalose emerges, not as a generic excipient, but as a genuine enabler of shelf life, safety, and innovation.
Look at trehalose dihydrate on a spectrum of sugars, and its stability stands out. Composed of two glucose molecules linked by an alpha-1,1-glycosidic bond, it resists acid hydrolysis and enzymatic attack. The dihydrate form incorporates two molecules of water per molecule, making it flowable but also a touch sensitive to drying. Melting hovers around 97°C when hydrated and 203°C when anhydrous. It offers a gentle sweetness (less than half as sweet as sucrose) and dissolves readily in water, essential for injectable and solution-based drugs. Its non-reducing nature means it won’t brown or degrade proteins during sterilization—a key advantage over other sugars.
Pharma-grade trehalose comes with stringent specifications. Manufacturers specify a minimum assay of 98-99% trehalose on a dry basis, microbial limits fit for injection or inhalation needs, controlled particle size for repeatability, and strict absence of endotoxin. Regulatory labels demand the specification of hydration state, batch number, expiration date, and all compliance codes—BP, EP, USP monographs—right on packaging drums. Pharmaceutical buyers check for Certificates of Analysis and traceability back to manufacturing batches, driven by GMP and PIC/S expectations. Each delivery comes with safety data, contamination risk assessments, and instructions grounded in real-life manufacturing needs.
Most commercially available trehalose dihydrate starts with plant starch—usually tapioca or corn. Companies deploy enzymes like trehalose synthase to convert linear starch molecules into trehalose in large fermenters. The resulting trehalose-rich solution goes through filtration, concentration, crystallization, and careful drying to preserve the two water molecules crucial for the dihydrate form. Quality control requires an arsenal of techniques: HPLC for purity, moisture analyzers, and microbiological testing to weed out contamination. The preparation sidesteps solvents or harsh chemicals, which aligns with safety-conscious pharmaceutical needs.
Trehalose claims a chemical backbone built for stability. Its structure shrugs off Maillard reactions and oxidative degradation, protecting delicate APIs from breakdown during processing and storage. Researchers explore minor chemical tweaks to the molecule. Esterification, phosphorylation, and even polymerization let scientists tailor trehalose’s solubility, rate of release, or biological activity. Pharmaceutical innovators look for ways to link trehalose with specific drug delivery systems or to build conjugates that exploit its water-binding properties for tissue protection or wound healing.
Product labels hide trehalose under names like alpha,alpha-trehalose, mycose, or mushroom sugar. In pharma procurement lists, it shows up as Trehalose Dihydrate BP/EP/USP or simply Trehalose 2H2O. Some firms market it under proprietary labels, but behind the brand names lurk the same core compound built on the dual-glucose structure. As industry focus shifts, expect more trade names to crop up, but global pharmacopoeia standards keep the underlying chemistry steady.
Handling trehalose dihydrate within a pharmaceutical plant involves more than donning gloves. Safety protocols align with cGMP expectations, calling for regular worker training on spill cleanup, PPE usage, and cross-contamination controls. Pharmacopeia standards keep microbial and endotoxin contamination in check. Real-world manufacturing relies on tight environmental monitoring—air filters, dust suppression, and rigorous equipment cleaning—since trehalose, like any excipient, cannot bring contamination risk into vaccines or injectables. Operators keep Material Safety Data Sheets at hand, documenting stability, reactivity, and first aid measures for accidental exposure.
Pharmaceutical trehalose sits at the core of protein formulation. It stabilizes antibodies, enzymes, and vaccines that would otherwise fall apart on the shelf. In lyophilized formulations, trehalose glassifies at low temperatures, locking proteins into a vitrified state and reducing aggregation. Drug development teams turn to trehalose as a cryoprotectant in cell therapies, protecting stem cells during freezing and thawing. Nasal sprays and injectables rely on it to minimize protein stress and ensure patient safety. Beyond injectables, trehalose emerges in tablets as a filler or as an osmoprotectant in ophthalmic eye drops, field-tested for comfort by dry eye patients.
Researchers test trehalose in everything from organ preservation to molecular diagnostics. Scientists target its ability to reduce oxidative damage during manufacture and transport. In my own pharma projects, trehalose solved challenges stabilizing a fragile enzyme through repeated freeze-thaws, outperforming mannitol, sucrose, and even polyols. Academics in biotechnology analyze trehalose’s action at the molecular level, studying its interactions with phospholipids or its potential to penetrate cells and prevent protein denaturation. Clinical trials evolve, seeking to validate trehalose’s effectiveness for neurological diseases, as it appears to reduce protein misfolding implicated in Huntington’s and Alzheimer’s.
Decades of research point to trehalose’s low toxicity profile. Human studies document high oral tolerance, with gram-level doses passing through healthy volunteers without ill effects. Studies in rodents confirm a lack of mutagenicity, carcinogenicity, or reproductive toxicity, giving regulators confidence in its safety for excipient use. Intravenous studies for vaccine and biologic applications look for pyrogenicity, hemolytic potential, and immunogenicity, and trehalose passes these hurdles consistently. My own team ran pharmacovigilance reviews tracking adverse reactions—real-world patients and manufacturing workers rarely experience issues, except for rare allergy or pre-existing metabolic disorder cases.
Trehalose dihydrate moves forward with the growth of biologics and personalized medicine. Next-generation gene and cell therapies require excipients delivering predictable safety and stabilization, and trehalose answers this call. Developers keep pushing its performance in extended shelf-life vaccines and oral formulations for chronic diseases. With research hinting at benefits in organ preservation, medical device coatings, and neuroprotective therapy, trehalose’s reach seems set for further expansion. The regulatory landscape continues to demand cleaner, safer, and more transparent ingredient sourcing, putting pressure on manufacturers to improve traceability and documentation. As more data emerges, pharmaceutical trehalose stands ready to evolve alongside modern medicine’s boldest challenges.
Trehalose dihydrate gets plenty of attention in pharmaceutical manufacturing these days. Anyone who's worked in drug development or helped keep a tablet stable in a warehouse knows this sugar has a reputation. Trehalose is a naturally occurring disaccharide made of two glucose molecules bound together, but in its pharma-grade form—whether BP, EP, or USP—you’re looking at a highly vetted ingredient. Its popularity in the pharmaceutical field hits a couple of key points: it protects delicate active ingredients and doesn't break down easily under normal storage conditions.
During my time in pharma labs, it became clear how tough it is to keep proteins and vaccines from falling apart. These compounds hate getting too warm, too cold, or simply sitting around too long. Trehalose seems to act like a bodyguard for these molecules, locking in their structure through a process called vitrification. In basic terms, trehalose forms a glassy layer that keeps sensitive drugs from losing their shape when dried or frozen. Teams use it when developing injectable drugs or biologics that need to maintain potency from factory to patient.
Tablets and powders that need to dissolve quickly or preserve their punch get a major boost from trehalose dihydrate. The sweet, non-reactive properties it brings to the table mean manufacturers can build chewable or sublingual tablets without a bitter aftertaste. Pediatric formulations—think flavored powders for reconstitution—show the benefit. These products must please picky young tastes while remaining shelf-stable. Trehalose covers both requirements: taste and durability.
The real headache in my field comes from stabilizing monoclonal antibodies and vaccines. Most proteins are fragile; oxygen and moisture can do real damage before the medicine reaches the clinic. Trehalose steps in as a cryoprotectant and lyoprotectant, making freeze-drying (lyophilization) possible without losing activity or safety profile. Bioengineers lean heavily on trehalose when making products for the global supply chain, where cold-storage logistics sometimes fail. Without this sugar, a lot of medical breakthroughs wouldn’t make it past customs, let alone safely to a rural health post.
People raise a valid question: is it safe to use more sugar in medications? Toxicologists and regulators keep a sharp eye on these ingredients. Trehalose has a long safety history, both as a food ingredient and in pharma. One review published in the International Journal of Pharmaceutics detailed how trehalose scores low for toxicity and supports cellular health, explaining its rising popularity among regulatory agencies across Europe, the United States, and Asia.
As medications get more complex, so do the challenges of keeping them reliable from production to administration. Trehalose will likely play an even bigger role in advanced therapies such as mRNA vaccines, which need special stabilization tricks. Some teams already experiment with trehalose in combination with other excipients for even better protection. Cost sometimes creates barriers to broader adoption, especially in low- and middle-income markets. Continuing to drive efficiencies in production and engaging in partnerships with public health entities stands out as one way to make these advanced ingredients available everywhere they're needed.
Pharmaceutical work pushes everyone to demand more from their raw materials. Trehalose dihydrate, a sugar used in formulas, brings this demand right to the surface. If purity falters, patient safety sways. Simple sugar molecules belong on the ingredient list—unwanted residues or microbial remains do not. Trehalose dihydrate pharma grade must clear strict standards. In my years supporting R&D teams, every process step pointed back to one big question: Is the lot really pharmaceutical grade, or is it just labeled that way?
Real-world standards for this ingredient are anchored in pharmacopeias like USP, EP, or JP. Purity sets the bar high, running above 98% and reaching often to 99% or greater. Specifications drive manufacturers to control for trace elements—residual solvents, heavy metals, and microbes. For instance, the lead content remains under 1 ppm, and arsenic under 2 ppm in reputable pharma sources. Endotoxin tests lock down safety, with microbial counts so low that even sensitive culture media rarely detect anything.
Every reputable supplier shares a COA for the batch. That certificate usually lists:
Manufacturer shortcuts or substandard batches eventually catch up to a team developing injectables or freeze-dried formulations. Impurities can trigger reactions in patients or hamper stability. For biologics makers, traces of unwanted sugars encourage bacteria to thrive or clog filters. On the regulatory side, contamination rarely slips past scrutiny. Auditors from the FDA or EMA dig deep, from paperwork to incoming goods storage.
I once watched a project stumble simply due to a slightly elevated metal level in a sugar supply. The stability studies ground to a halt. That cost months. Every approval hinges on predictable, documented, tested quality. High costs and delays follow every unwelcome surprise.
Developing trust in an ingredient like trehalose dihydrate means building long relationships with quality-focused suppliers. Regular audits help, but in-house testing on every new shipment makes the difference. Purchasing only from GMP-certified, transparent suppliers limits risk. Some teams rely on multiple sources to insulate their projects against abrupt shortages or changes in raw material consistency.
For buyers and formulators, tightly controlled documentation beats marketing claims every time. That means reviewing certificates of analysis, knowing which pharmacopeia methods apply, and double-checking test results. Over time, tracking lot-to-lot variability supports better forecasting for both manufacturing and regulatory review.
The details matter, and the patients at the other end of the process deserve nothing less.
Trehalose dihydrate crops up in labs and kitchens more often than people realize. It’s a type of sugar, packed into tablets and baked goods, that manages to taste sweet without wrecking your blood sugar the way table sugar does. Conscious eaters see it on labels, and pharmacists often see it as a bulking agent in medications that need stability.
Plenty of folks worry about new names on ingredient panels, but trehalose is not as exotic as it sounds. Mushrooms and plants contain these molecules in large amounts. Even shrimp and some insects pick up trehalose naturally through their diet. Japan led a lot of the research on this sugar back in the late 20th century, and scientists there gave it the green light for safe use in ordinary foods after a battery of tests.
Major health authorities like the European Food Safety Authority (EFSA) and the US Food and Drug Administration (FDA) followed up with their own research. Both have ruled trehalose safe as an ingredient for human foods, including those given to children and sick patients. The World Health Organization and JECFA call it safe for “general population” use. For pharmaceuticals, it passes the tests for non-toxicity, non-reactivity, and non-carcinogenicity.
A big question still hangs over how our bodies process this sugar. Trehalose breaks down into two glucose molecules after contact with an enzyme in the small intestine. For most healthy people, this causes no problems. I’ve read research showing that even large amounts—up to 50 grams at once—tend to get absorbed without gastric flare-ups.
Not all bodies react the same. Some folks, especially those with a rare deficiency in the trehalase enzyme, can’t split this sugar. These people tend to notice bloating, cramps, or diarrhea after eating products made with trehalose. The numbers are pretty low, though, with trehalase deficiency most common in certain East Asian groups. Still, labeling needs to be clear so everyone can make informed choices.
Trehalose shows up in vaccines, protein formulations, and tablets for a reason. Medications spoil fast without a stabilizer, and trehalose locks in structure and function better than regular sugars. I’ve seen manufacturers switch to trehalose when working with live enzymes and delicate proteins. Most findings show trehalose doesn’t set off allergic reactions or toxic effects.
Still, a small number of reports suggest trehalose could support the growth of a bacterial strain called Clostridium difficile in the gut. This strain disrupts digestion and causes colitis, an illness with painful symptoms. Some researchers believe trehalose spurred an increase in these cases, especially in hospitals, but there’s debate. Most evidence points to antibiotics and hospital-sterile practices as main culprits. I believe care teams should consider this risk for patients already at high risk for gut infection, without demonizing trehalose for healthy people.
Safe food and medicines begin with open information. Clear product labels, up-to-date research, and honest conversations with doctors all build trust. Based on the evidence, trehalose dihydrate supports stable products in pharmacy and food. For folks with underlying digestive disorders, or rare enzyme deficiencies, extra attention to ingredient lists keeps their options safe too.
Innovation often stirs anxiety, especially when new ingredients like trehalose join the scene. With steady science, strong safety testing, and respect for different health needs, people benefit from safer, more reliable products.
Trehalose Dihydrate stands out in industries where stability and purity matter. Chemists often look for packaging that preserves its crystalline structure, whether they’re formulating tablets or working in food processes. At the warehouse, I see two styles of packaging all the time. Fiber drums with tight-fitting polyethylene liners, and multi-layered polyethylene bags, both catch the attention of buyers seeking protection against moisture and air.
A fiber drum houses larger bulk shipments, usually in 25 or 50 kg sizes. They stack well, and those polyethylene liners keep stray humidity away from the contents. Smaller batches tend to ship in double-layer polyethylene bags—less waste, easier handling. Both approaches aim for one thing: dry, uncontaminated product from start to finish.
I’ve seen quality fall apart when trehalose soaks up water. Even a little humidity introduces clumps or can set off microbial growth. That’s why the best suppliers store trehalose away from direct sunlight, in cool, dry warehouses. Long experience tells me that opening a caked-together bag means trouble ahead, whether it’s a sampling issue in the lab or a headache for the mixing operator.
High-grade trehalose almost always carries a “best before” date between 24 and 36 months from manufacturing. This window keeps things safe and meets pharmaceutical performance standards. I met a production manager who swears by checking every drum label—the dates, the lot numbers, the integrity of the seal—because rejecting a shipment after months in storage costs time and money nobody wants to lose.
Here, real-world conditions count. Moisture breaks down shelf life fast. It isn’t about perfect lab storage. Once a warehouse gets too hot or air leaks into that bag or drum, shelf life drops. I recommend regular checks of temperature and humidity; some setups even use sensors now, logging data to prevent loss.
Trehalose is tough by sugar standards, but stable storage is never guaranteed by packaging alone. Pharmaceutical processors, for example, require not just a clean compound but evidence it hasn’t degraded. I’ve learned you can never trust visual inspection alone—testing at intervals is the only way to catch surprises.
Global demand for trehalose crosses pharmaceuticals, food, and even cosmetics. Batch traceability and tight quality control only matter if the material’s condition stays consistent. I suggest building partnerships with trusted suppliers—those who disclose their packaging specs up front and who rotate stocks to keep everything fresh.
There’s always temptation to save money by buying in bulk or using off-brand packaging, but every shortcut raises the risk of spoilage. Because trehalose supports everything from pill binders to sensitive protein formulas, cutting corners doesn’t pay. Rely on fiber drums or sturdy liners, keep warehouses cool and dry, check labels before use, and rotate inventory to keep shelf life intact.From my experience, that habit separates the best-run operations from those chasing after replacements.
Pharmaceutical manufacturing rarely leaves room for shortcuts. Trehalose dihydrate stays in steady demand for projects in vaccine preservation, tablet making, and many therapeutic innovations. Everyone in the supply chain, from chemists to procurement leads, deals with the same reality: not every barrel on the market promises the reliability and safety that British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP) standards demand.
Anyone who has spent real time in formulation labs knows the anxiety that follows a failed batch due to raw material impurities. Deviations from BP, EP, or USP compliance make it easier for things like heavy metal content, microbial contamination, or inconsistent particle size to seep into the production floor. Regulatory citations follow closely behind.
A batch failing to meet BP, EP, and USP limits on impurities can derail launch timelines, drive up costs, and create a nightmare when it comes to root cause investigations. It’s more than an inconvenience. Patient safety hangs in the balance, not to mention business viability. In my own work, we once saw a promising trial delayed by several months—just because a supposedly “compliant” excipient didn’t truly pass all the listed monograph tests. Sometimes, even a trace contaminant gives auditors enough reason to hold up production and threaten product withdrawal.
The industry often faces regulatory scrutiny for underestimating how much excipient grade purity impacts therapeutic consistency. The USP, for instance, has done studies showing how contaminants can sneak into the process when oversight slips. By the time someone traces the source, costs have ballooned and public trust wavers.
BP, EP, and USP monographs provide guardrails, not just checkboxes. Each standard puts heavy focus on aspects like water content, clarity, microbial load, and residual solvents. Trehalose dihydrate that clears these hurdles fits better in a world where reproducible drug quality is a requirement, not an aspiration. Skipping these controls means putting everything at risk—reputation, licenses, and most importantly, end-user safety.
Sourcing managers and quality teams hold the front line. Asking for full certificates of analysis and third-party lab verification brings peace of mind downstream. I always advocate for reading the fine print—not just the vendor’s claims but actual test data for each pharmacopoeia’s requirements. Site audits help make sure suppliers don’t cut corners.
Solid recordkeeping creates a strong defense during regulatory inspections. A reliable digital batch record system, reviewed regularly, can catch trends before they cause harm. For firms handling lots of sensitive molecules, it pays to stick close to suppliers who willingly open their labs to scrutiny—and back up every shipment with the real data.
Those of us responsible for product launches or maintaining GMP licenses know regulatory bodies will spot inadequate documentation faster than ever. New technologies can add extra layers of verification, but the basics never change: know your supplier, scrutinize their compliance claims, and document everything.
Drug safety depends on transparent supply chains. Clients and patients trust pharmaceutical companies to use ingredients that won’t let them down. Trehalose dihydrate’s role in stabilizing APIs, lyophilized products, and vaccines ensures it sits close to the heart of healthcare. Missing BP, EP, or USP benchmarks doesn’t just slow business. It threatens to unravel everything teams have worked for—including patient well-being.
| Names | |
| Preferred IUPAC name | α-D-glucopyranosyl-(1→1)-α-D-glucopyranoside dihydrate |
| Other names |
Trehalose α,α-Trehalose Trehalose Anhydrous Trehalose Dihydrate Ph Eur Trehalose Dihydrate USP Trehalose Dihydrate BP Pharmaceutical Grade Trehalose Mycose |
| Pronunciation | /triːˈhæləʊs daɪˈhaɪdreɪt biː piː iː piː ˈjuː ɛs piː ˈfɑːrmə ɡreɪd/ |
| Identifiers | |
| CAS Number | 6138-23-4 |
| Beilstein Reference | 3594482 |
| ChEBI | CHEBI:36010 |
| ChEMBL | CHEMBL1201521 |
| ChemSpider | 5414423 |
| DrugBank | DB13094 |
| ECHA InfoCard | 03b4f2ec-5be6-460a-baa0-108ded2a418d |
| EC Number | 6138-23-4 |
| Gmelin Reference | 63747 |
| KEGG | C00492 |
| MeSH | Dihydroxyacetone |
| PubChem CID | 6918756 |
| RTECS number | TY2000000 |
| UNII | Z3R4TUX2IX |
| UN number | Non-regulated |
| CompTox Dashboard (EPA) | DTXSID2097082 |
| Properties | |
| Chemical formula | C12H22O11·2H2O |
| Molar mass | 378.33 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.58 g/cm³ |
| Solubility in water | Easily soluble in water |
| log P | “-11.73” |
| Acidity (pKa) | 12.35 |
| Basicity (pKb) | 11.71 |
| Refractive index (nD) | 1.333 |
| Viscosity | 2.12 cP (20% aqueous solution at 20°C) |
| Dipole moment | 0.00 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 260.6 J·K⁻¹·mol⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -2476.6 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -5637 kJ/mol |
| Pharmacology | |
| ATC code | A16AX11 |
| Hazards | |
| Main hazards | Not hazardous according to GHS classification. |
| GHS labelling | GHS labelling: Not a hazardous substance or mixture according to the Globally Harmonized System (GHS) |
| Pictograms | GHS07 |
| Hazard statements | No hazard statements. |
| Precautionary statements | Store in a tightly closed container, in a cool, dry place. Avoid inhalation of dust, contact with eyes, skin, and clothing. Use with adequate ventilation. Wash thoroughly after handling. |
| Lethal dose or concentration | LD50 Oral Rat 15,800 mg/kg |
| LD50 (median dose) | Oral-rat LD50: > 15,000 mg/kg |
| NIOSH | Not listed by NIOSH |
| PEL (Permissible) | 10 mg/m³ |
| REL (Recommended) | 0.5 mg/kg bw |
| Related compounds | |
| Related compounds |
Trehalose Anhydrous Trehalose Maltose Sucrose Lactose Mannitol Sorbitol Glucose Fructose Dextrin |
Chengguan District, Lanzhou, Gansu, China
